Ephedrine Alkaloids Dosing, Duration Limits Withdrawn Pending Public Input
This article was originally published in The Tan Sheet
Executive Summary
FDA will consider "public comment of the widest kind" from the "layperson to health professionals to scientists" in analyzing and changing portions of the June 1997 proposed rule on ephedrine alkaloids in dietary supplements, Commissioner Jane Henney, MD, testified at a congressional hearing Feb. 29.
You may also be interested in...
Ephedra Ban Court Challenge Could Be Good News For FDA, Win Or Lose
FDA's decision to ban ephedra outright creates a win-win situation for the agency, regardless of whether the regulation stands up in court
Ephedra “Imminent Hazard” Declaration Sought By Sen. Durbin
Sen. Dick Durbin (D-Ill.) is pressing HHS Secretary Tommy Thompson to take immediate action against the sale of ephedra weight-loss dietary supplements by declaring the herbal ingredient an "imminent hazard.
Ephedra/AER Causality Link Not Possible - Cantox/CRN
Ephedrine alkaloid adverse event reports recorded in FDA's Special Nutritional Adverse Event Monitoring System do not establish causation between supplements containing the popular weight loss and sports herbal ingredient and reported AEs, according to a report commissioned by the Council for Responsible Nutrition.